Citations 1
TOPACIO/Keynote-162 (NCT02657889): A phase 1/2 study of niraparib + pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)—Results from ROC cohort.
Konstantinopoulos, Panagiotis A. , Waggoner, Steven , Vidal, Gregory A. , Mita, Monica , Holloway, Robert W. , Le, Linda Van, Sachdev, Jasgit C. , Chapman‐Davis, Eloise , Colón‐Otero, Gerardo , Penson, Richard T. , Matulonis, Ursula A. , Kim, Young B., Dezube, Bruce J., Wang, Jing Y., Buerstatte, Nathan, Arora, Sujata, Münster, Pamela N. , Munster, Pamela , Konstantinopoulos, Panagiotis A , Fleming, Gini F. , Moore, Kathleen N. , Swisher, Elizabeth M.
Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 106-106
